Endocrine therapy regimens for the primary breast cancer can both improve survival and reduce the risk of developing contralateral breast cancer among women with estrogen receptor positive (ER+) and human epidermal growth factor receptor negative (HER2-) breast primary cancers3–7, which constitute nearly two-thirds of all primary breast cancers8. The gene discussed is ERBB2; the disease is breast carcinoma.